- Home
- EHC vs BMRN Comparison
EHC vs BMRN Comparison
Compare EHC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHC | BMRN |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.5B |
| IPO Year | 1986 | 1999 |
Fundamental Metrics
Financial Performance| Metric | EHC | BMRN |
|---|---|---|
| Price | $106.96 | $53.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 19 |
| Target Price | ★ $141.88 | $88.42 |
| AVG Volume (30 Days) | 762.2K | ★ 2.9M |
| Earning Date | 10-29-2025 | 10-27-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | 27.89 | ★ 59.53 |
| EPS | ★ 5.29 | 2.68 |
| Revenue | ★ $5,795,600,000.00 | $3,094,001,000.00 |
| Revenue This Year | $11.54 | $13.39 |
| Revenue Next Year | $8.78 | $7.57 |
| P/E Ratio | $20.23 | ★ $19.89 |
| Revenue Growth | 11.13 | ★ 12.39 |
| 52 Week Low | $87.85 | $50.76 |
| 52 Week High | $127.99 | $73.51 |
Technical Indicators
Market Signals| Indicator | EHC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 27.57 | 46.21 |
| Support Level | $105.71 | $52.55 |
| Resistance Level | $117.50 | $54.33 |
| Average True Range (ATR) | 2.28 | 1.24 |
| MACD | -0.54 | -0.17 |
| Stochastic Oscillator | 10.61 | 19.23 |
Price Performance
Historical ComparisonAbout EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.